{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-24-000055","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.005740+00:00","generated_at":"2026-05-30T04:22:48.282583+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Amphastar Q3 2024 revenue up 5.9% to $191.2M; adjusted EPS down to $0.96","bullets":["Net revenues $191.2M vs $180.6M in Q3 2023, up 5.9%.","GAAP net income $40.4M ($0.78 diluted EPS) vs $49.2M ($0.91) year ago.","Adjusted non-GAAP net income $49.6M ($0.96 diluted EPS) vs $61.9M ($1.15).","Growth driven by BAQSIMI and Primatene MIST; Primatene on track for $100M annual sales.","No updated guidance provided in the release."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-24-000055","json":"https://secwatch.observer/filing/0001297184-24-000055.json","markdown":"https://secwatch.observer/filing/0001297184-24-000055.md","text":"https://secwatch.observer/filing/0001297184-24-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718424000055/0001297184-24-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718424000055/amph-20241106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:22:48.282583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}